April 2013

ABOUT AUTHORS:
Vishal V. Timaliya*, Prof.Mital v. Dalal
Gujarat Technical University
*vishal.vishal.timaniya@gmail.com

ABSTRACT
The main objectives of this study were the prevalence of depression and cognitive function impairments in patients undergoing hemodialysis.
An observational study performed on 60 patients with CKD stage IV and V undergoing hemodialysis two or three times in a week and CKD stage I to III without hemodialysis. Depressive symptomatology, defined by a Center for Epidemiological Studies Depression Scale (CES-D) score of 16 or higher and cognitive function measured by Mini Mental State Examination (MMSE) questionnaire. All data was analyzed by MS excel and Graph pad Prism 5.0.

While there is a huge opportunity for pharmaceutical and Healthcare companies to sell their products in emerging markets due to rising incomes, higher incidence of chronic and lifestyle diseases, better insurance coverage, and better patent protection regimes for drugs, major roadblocks such as lack of mature distribution networks, lower price points due to generics competition, and counterfeiting are leaving even the large companies struggling to handle the challenges from some of these less sophisticated markets. Local business partnerships and better understanding and responsiveness to cultural differences will be very important in determining the success in emerging markets.

ASSOCHAM in its quest to resolve these issues and create a fine link through global regulators and industry experts, and bring first hand information at the disposal are some of the objectives aimed through ASSOCHAM’s unique endeavour “GCT 2013 ? Challenges & Opportunities”

Participation Details
Due to the support of Department of Biotechnology, Government of India, ASSOCHAM wave off the Registration fees for GCT 2013; Generic Drugs, Clinical Trials & Technology Conference at Hotel Metropole, Ahmedabad on 30th April 2013.

IICB Institute was established in 1935 as the first non official centre in India for biomedical research and was included within the aegis of CSIR in 1956.
IICB today is engaged in research on diseases of national importance and biological problems of global interest, employing sophisticated state-of-the-art technology in keeping with the rapid and unprecedented momentum that life science research has gained globally over the last 50 years.

MSD Wellcome Trust Hilleman Laboratories (Hilleman Labs), is a joint venture between Merck & Co., Inc. (which operates in India as MSD Pharmaceuticals Pvt. Ltd.) and Wellcome Trust (which is a UK based research charity).

Applications are to be submitted by eligible candidates as per prescribed format available on the website wbmsc.co.in, wbmsc.gov.in OR wbhealth.gov.in Details of job requirements and process of selection are also available on the above websites. All applications should be addressed to The Managing Director, West Bengal Medical Services Corporation Limited, Swasthya Bhawan Complex, GN-29, Sector – V, Salt Lake, Kolkata – 700 091.